Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data.

Abstract

This paper has reviewed the documentation on the clinical efficacy of choline alphoscerate, a cholinergic precursor, considered as a centrally acting parasympathomimetic drug in dementia disorders and in acute cerebrovascular disease. Thirteen published clinical trials, examining in total 4054 patients, have evaluated the use of choline alphoscerate in various forms of dementia disorders of degenerative, vascular or combined origin, such as senile dementia of the Alzheimer's type (SDAT) or vascular dementia (VaD) and in acute cerebrovascular diseases, such as transitory ischemic attack (TIA) and stroke. Analysis has assessed the design of each study, in particular with respect to experimental design, number of cases, duration of treatment and tests used to evaluate drug clinical efficacy. Most of the ten studies performed in dementia disorders were controlled trials versus a reference drug or placebo. Overall, 1570 patients were assessed in these studies, 854 of which in controlled trials. As detected by validated and appropriate tests, such as Mini Mental State Evaluation (MMSE) in SDAT and Sandoz Clinical Assessment Geriatric (SCAG) in VaD, administration of choline alphoscerate significantly improved patient clinical condition. Clinical results obtained with choline alphoscerate were superior or equivalent to those observed in control groups under active treatment and superior to the results observed in placebo groups. Analysis stresses the clear internal consistency of clinical data gathered by different experimental situations on the drug effect, especially with regard to the cognitive symptoms (memory, attention) characterising the clinical picture of adult-onset dementia disorders. The therapeutic usefulness of choline alphoscerate in relieving cognitive symptoms of chronic cerebral deterioration differentiates this drug from cholinergic precursors used in the past, such as choline and lecithin. Three uncontrolled trials were performed with choline alphoscerate in acute cerebrovascular stroke and TIA, totalling 2484 patients. The results of these trials suggest that this drug might favour functional recovery of patients with cerebral stroke and should be confirmed in future investigations aimed at establish the efficacy of the drug in achieving functional recovery of patients with acute cerebrovascular disease.

• Authors: L Parnetti, F Amenta, V Gallai
• Journal: Mechanisms of ageing and development (Mech Ageing Dev) Vol. 122 Issue 16 Pg. 2041-55 (Nov 2001) ISSN: 0047-6374 [Print] Ireland
• PMID: 11589921 (Publication Type: Journal Article)

Chemical References

• Parasympathomimetics
• Glycerylphosphorylcholine

Topics

• Cerebrovascular Disorders (drug therapy)
• Clinical Trials as Topic
• Cognition Disorders (drug therapy)
• Dementia, Vascular (drug therapy)
• Glycerylphosphorylcholine (therapeutic use)
• Humans
• Parasympathomimetics (therapeutic use)
• Periodicals as Topic
• Statistics as Topic